The CEO of Swiss pharmaceutical giant Galderma believes that the rise in popularity of weight-loss drugs like Ozempic could have a significant impact on its facial fillers business. Flemming Ornskov, the CEO of Galderma, mentioned to Bloomberg that Ozempic can sometimes cause a sunken-in appearance in patients' faces. He noted that fillers could be used to counteract this effect, potentially leading to a new growth wave in the fillers market that Galderma aims to capitalize on.
Galderma's Response and Initiatives
Galderma, known for its skin care treatments, offers products like Sculptra that are designed to address the gaunt look associated with the so-called "Ozempic face." Ornskov revealed that the company is exploring the increasing use of GLP-1 treatments as an opportunity for Injectable Aesthetics. A spokesperson from Galderma confirmed that the company is conducting a study to assess the impact of Sculptra and two types of Restylane on cheek augmentation and contour deficiencies in GLP-1 patients. The spokesperson indicated that initial results from the study may be available by the end of the year.
Expert Insights and Observations
According to dermatologists interviewed by Business Insider, the phenomenon of "Ozempic face" has become prevalent in clinical practice. Dr. Joshua Zeichner noted a significant increase in patients presenting with this concern, attributing it to the widespread use of medications like Ozempic. Cosmetic dermatologist Dr. Paul Jarrod Frank, credited with coining the term "Ozempic face," explained that the effect is often a result of aging and rapid weight loss.
Recent Developments and Performance
Galderma recently went public on the SIX Swiss Exchange, with shares experiencing a surge in value, as reported by Reuters. The company's first-quarter sales reached $1 billion, marking a 12.4% year-over-year increase. The success of Galderma's products and strategic initiatives underscores its position as a key player in the pharmaceutical and aesthetics market.
—————————————————————————————————————————————
By: insider@insider.com (Geoff Weiss,Julia Pugachevsky)
Title: How Weight-Loss Drug Ozempic Could Impact the Facial Fillers Market
Sourced From: www.businessinsider.com/pharma-giant-galderma-cashing-in-ozempic-face-with-fillers-2024-4
Published Date: Thu, 25 Apr 2024 17:54:26 +0000
Leave a Reply